Roadzen enters Fiscal Year 2026 with Momentum and Improved Operating Leverage Driven by Strong Performance in the U.S. and India and a $300+Million Pipeline Key Highlights – Fiscal Year 20251. Revenue Growth Returns in Q4Roadzen reported full-year revenue of $44.3 million, a 5.2% decline year-over-year due to the temporary suspension of GAP insurance sales in the U.K, which impacted an estimated $27 million in annualized revenues of the Company in FY2025. In Fiscal Q4, Roadzen returned to top-line growth, delivering 13.3% year-over-year revenue growth to $11.3 million, up from $10.0 million in Q4 FY2024, led by strong performance in India and the U.S. which offset the prior-year U.K. pause.   2. Q4 99% Net Loss Reduction and Lower Adjusted EBITDA1 LossRoadzen nearly posted net income breakeven for the first time in Q4, with net...

Bollène (France), June 26, 2025 – 06 :00pm (CET)Press Release Update of the 2024 financial statements and Position of the Statutory Auditors Egide Group (Euronext Growth Paris™- ISIN: FR0000072373 – Ticker: ALGID), worldwide provider of hermetic packages and connectors and heat dissipation solutions for sensitive electronic components, announces today the update of its 2024 financial statements following audit work conducted by its Statutory Auditors. In a press release dated April 30, 2025, Egide published its 2024 annual results. Following the audit procedures, additional elements led the Board of Directors, which met today, to proceed with a restatement of the 2024 financial statements. ADJUSTMENT OF 2024 FINANCIAL STATEMENTSACCOUNTSAs a reminder, the 2024 results are now presented under French GAAP rather than IFRS. The...

Flow Traders 2Q 2025 Pre-close Call Amsterdam, the Netherlands – Flow Traders Ltd. (Euronext: FLOW) publishes the 2Q 2025 pre-close call script to be used with analysts post the market close on 26 June 2025. Eric Pan – Head of Investor Relations, Flow Traders Welcome to the Flow Traders 2Q 2025 pre-close call, which is being conducted post the European market close on 26 June. During this call I will highlight relevant publicly available data and industry trends in our markets as well as previously published data by Flow Traders and relate these data points to their impact on our business for the quarter. The silent period for 2Q will begin on 30 June and we will publish our 2Q 2025 results on 31 July at 07:30 CEST. Market Environment Market trading volumes and volatility increased in the second quarter across most asset classes...

LONDON, June 26, 2025 – Stolt-Nielsen Limited (Oslo Børs: SNI) will host a virtual presentation to discuss the Company’s unaudited results for the second quarter and first half of 2025 on Thursday, July 3, 2025 at 15:00 CEST (09:00 EDT, 14:00 BST). The virtual presentation will be hosted by: –           Mr. Udo Lange – Chief Executive Officer, Stolt-Nielsen Limited  –           Mr. Jens F. Grüner-Hegge – Chief Financial Officer, Stolt-Nielsen Limited –           Mr. Alex Ng – Vice President Strategy & Business Development, Stolt-Nielsen Limited To join the event online, please click here. The link will also be available on our website. It may be necessary to download the Teams app to join by mobile phone, although attendees should not need to log in or create an account. The presentation slides...

Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA® at medical conferences and a planned KOL event MDNA11 continues to exhibit compelling deep and durable anti-tumor activity in difficult-to-treat solid tumors with best-in-class potential relative to competing IL-2 programs Results presented at the 2025 AACR showed response rates in the 30-50% range in various tumor cohorts amongst high dose patients with tumor types being enrolled in Phase 2 Three cancer patients treated with MDNA11 remain tumor free since achieving complete resolution of all target and non-target lesions MDNA11 Phase 2b development plan to be solidified by end of calendar year, including evaluation of strategies for accelerated...

Strong Performance Delivers Sales Growth in Both Lighting and Intelligent SpacesDelivered Net Sales of $1.2B, an Increase of 22% Compared to the Prior Year Delivered Operating Profit of $140M, Down 4 % Compared to the Prior Year; Grew Adjusted Operating Profit to $222M, Up 33% Compared to the Prior Year Delivered Diluted EPS of $3.12, Down 14% Compared to the Prior Year; Grew Adjusted Diluted EPS to $5.12, Up 23% Compared to the Prior YearATLANTA, June 26, 2025 (GLOBE NEWSWIRE) — Acuity Inc. (NYSE: AYI), (“Acuity”), a market-leading industrial technology company, delivered net sales of $1.2 billion in the third quarter of fiscal 2025 ended May 31, 2025, an increase of $210.5 million, or 21.7 percent, compared to the prior year. “We delivered strong performance in the third quarter of fiscal 2025,” stated...

LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing   Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia, June 25, 2025 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2025 (“FYE 2025”), and provided an update on fiscal 2026. All figures are stated in Canadian dollars unless otherwise stated. “The recent commercial re-launch of LIKMEZ® (ATI-1501), following new patent coverage through to 2039, marked a major milestone for Appili and our partner, Saptalis Pharmaceuticals, LLC (“Saptalis”)....

TORONTO, June 25, 2025 (GLOBE NEWSWIRE) — Clairvest Group Inc. (TSX: CVG) today reported results for the fourth quarter and year ended March 31, 2025 and events which occurred subsequent to year end. (All figures are in Canadian dollars unless otherwise stated) HighlightsMarch 31, 2025 book value was $1,251.6 million or $88.30 per share compared with $1,234.3 million or $86.78 per share as at December 31, 2024 and $1,176.3 million or $80.16 per share as at March 31, 2024 Net income for the fourth quarter was $20.7 million or $1.46 per share as the fair value of certain investments increased Net income for fiscal 2025 was $122.0 million or $8.47 per share. During fiscal 2025, Clairvest had $46.1 million of net realized gains from the realization of four investments and $44.8 million of net investment gains on its remaining private...

Following a 198% sales surge in Q4, Hapbee added 191% revenue growth in Q1 2025 while reducing operating expenses by 62% VANCOUVER, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) — Hapbee Technologies Inc. (TSXV: HAPB | OTCQB: HAPBF), (“Hapbee” or the “Company”), the digital wellness technology company pioneering the science of bio-streaming, announces this clarification of its earlier press release dated June 24, 2025. This clarification is being issued at the request of the Canadian Investment Regulatory Organization (CIRO). Building on the momentum of Q4 2024, Hapbee entered 2025 with continued growth in sales – delivering meaningful growth in sales, notable reductions in operating expenses, and strategic improvements across its product and platform ecosystem. The Company’s Q1 performance results underscore Hapbee’s...

DELTA, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) — WestBond Enterprises Corporation (TSX-V: WBE) has posted a loss of $52,380 for the year ended March 31, 2025 ($210,683 loss for the year ended March 31, 2024). The value ascribed to stock options granted during the year contributed to this small loss. Sales increased 4.9% to $9,673,002 this year compared to $9,219,948 for the year ended March 31, 2024. The increase in revenue is the result of an increase in sales of wipe products and air-laid napkins and parent rolls, offset by a decrease in sales of personal hygiene, clinical, and other product categories. The addition of production staff, materials handling personnel and new equipment helped reduce the inefficiencies from the previous year. Sales are expected to increase as we continue to manage inquiries from our current...